Skip to main content
SpringerLink
Log in

Clinical Utility of the New ASAS Criteria for Spondyloarthritis and the Disease Activity Score

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

The advent of new therapeutic agents that are efficacious in the treatment of ankylosing spondylitis and related spondyloarthropathies has highlighted important unmet needs in our understanding of these conditions. Chief among these is the possibility of making a diagnosis at the early, nonradiographic phase, when the burden of disease is substantial and comparable to that of more advanced stages. The new Assessments in Spondyloarthritis International Society (ASAS) classification criteria provide a unique tool to allow research standardization in this area and may also be of clinical utility. The development of the disease activity index ASDAS (Ankylosing Spondylitis Disease Activity Score) aims to provide a composite measure that can discriminate and show sensitivity to change while incorporating measurable biomarkers. Both instruments represent a major step forward in the research field of spondyloarthritis, although further validation is now required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum. 1984;27(4):361–8.

    Article  PubMed  Google Scholar 

  2. Dougados M. Diagnostic features of ankylosing spondylitis. Br J Rheumatol. 1995;34(4):301–3.

    Article  PubMed  CAS  Google Scholar 

  3. Mau W, Zeidler H, Mau R, Majewski A, Freyschmidt J, Stangel W, et al. Clinical features and prognosis of patients with possible ankylosing spondylitis. Results of a 10-year followup. J Rheumatol. 1988;15(7):1109–14.

    PubMed  CAS  Google Scholar 

  4. Zochling J, van der Heijde D, Dougados M, Braun J. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis. 2006;65(4):423–32.

    Article  PubMed  CAS  Google Scholar 

  5. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J. Conventional treatments for ankylosing spondylitis. Ann Rheum Dis. 2002;61 Suppl 3:iii40–50.

    PubMed  CAS  Google Scholar 

  6. Chen J, Liu C. Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev. 2005;2:CD004800.

    PubMed  Google Scholar 

  7. Dougados M, vam der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, et al. Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum. 1995;38(5):618–27.

    Article  PubMed  CAS  Google Scholar 

  8. Clegg DO, Reda DJ, Abdellatif M. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study. Arthritis Rheum. 1999;42(11):2325–9.

    Article  PubMed  CAS  Google Scholar 

  9. Chen J, Liu C. Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol. 2006;33(4):722–31.

    PubMed  CAS  Google Scholar 

  10. Braun J, Zochling J, Baraliakos X, Alten R, Burmester G, Grasedyck K, et al. Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis. 2006;65(9):1147–53.

    Article  PubMed  CAS  Google Scholar 

  11. Chen J, Liu C. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2004;3:CD004524.

    PubMed  Google Scholar 

  12. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev. 2006;4:CD004524.

    PubMed  Google Scholar 

  13. Brandt J, Khariouzov A, Listing J, Haibel H, Sorensen H, Grassnickel L, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum. 2003;48(6):1667–75.

    Article  PubMed  CAS  Google Scholar 

  14. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet. 2002;359(9313):1187–93.

    Article  PubMed  CAS  Google Scholar 

  15. Davis Jr JC, Van Der Heijde D, Braun J, Dougados M, Cush J, Clegg DO, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum. 2003;48(11):3230–6.

    Article  PubMed  CAS  Google Scholar 

  16. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52(2):582–91.

    Article  PubMed  Google Scholar 

  17. van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(7):2136–46.

    Article  PubMed  Google Scholar 

  18. Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58(7):1981–91.

    Article  PubMed  CAS  Google Scholar 

  19. Barkham N, Keen HI, Coates LC, O’Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum. 2009;60(4):946–54.

    Article  PubMed  CAS  Google Scholar 

  20. Rudwaleit M, Haibel H, Baraliakos X, Listing J, Marker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60(3):717–27.

    Article  PubMed  CAS  Google Scholar 

  21. Rudwaleit M, Landewe R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68(6):770–6.

    Article  PubMed  CAS  Google Scholar 

  22. •• Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68(6):777–83. In this study, the ASAS criteria for axial SpA were validated in a cohort of 649 patients with chronic back pain.

    Article  PubMed  CAS  Google Scholar 

  23. Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. Curr Opin Rheumatol 22(4):375–80.

  24. • Rudwaleit M, Jurik AG, Hermann KG, Landewe R, van der Heijde D, Baraliakos X, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009;68(10):1520–7. This report describes a consensus statement by the ASAS/OMERACT MRI expert working group on the definition of positive magentic resonance signal representing active sacroiliitis in SpA. This definition was meant to provide guidance on the interpretation of MRI to be applied in the imaging arm of the new ASAS criteria for axial SpA.

    Article  PubMed  CAS  Google Scholar 

  25. •• Bennett AN, McGonagle D, O’Connor P, Hensor EM, Sivera F, Coates LC, et al. Severity of baseline magnetic resonance imaging-evident sacroiliitis and HLA-B27 status in early inflammatory back pain predict radiographically evident ankylosing spondylitis at eight years. Arthritis Rheum 2008;58(11):3413–8. The results of this study show that in patients with early IBP, a combination of severe sacroiliitis and HLA–B27 positivity has a high specificity for the development of AS compared with mild or no sacroiliitis, regardless of HLA–B27 status, which confers a low likelihood of developing AS.

    Article  PubMed  CAS  Google Scholar 

  26. • Marzo-Ortega H, McGonagle D, O’Connor P, Hensor EM, Bennett AN, Green MJ, et al. Baseline and 1-year magnetic resonance imaging of the sacroiliac joint and lumbar spine in very early inflammatory back pain. Relationship between symptoms, HLA-B27 and disease extent and persistence. Ann Rheum Dis 2009;68(11):1721–7. This study reported the results of lumbar and SIJ MRI from 54 patients with IBP, and the relationship between sites and extent of inflammation and HLA-B27 status over 12 months. The results show that lumbar spine and SIJ involvement may occur simultaneously in very early SpA and may be differentiated from noninflammatory back pain by the severity of MRI lesions, and that HLA-B27 is associated with the severity of osteitis and its persistence.

    Article  PubMed  CAS  Google Scholar 

  27. Aydin S, Bennett A, Emery P, McGonagle D, Marzo-Ortega H. The new ASAS criteria for axial SpA does not predict the development of mNYC AS at 8 years in a cohort of very early IBP patients [abstract]. Arthritis Rheum. 2010;62 suppl 10:553.

    Google Scholar 

  28. Weber U, Lambert RG, Pedersen SJ, Hodler J, Ostergaard M, Maksymowych WP. Assessment of structural lesions in sacroiliac joints enhances diagnostic utility of magnetic resonance imaging in early spondylarthritis. Arthritis Care Res (Hoboken). 2010;62(12):1763–71.

    Article  Google Scholar 

  29. Weber U, Lambert RG, Ostergaard M, Hodler J, Pedersen SJ, Maksymowych WP. The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects. Arthritis Rheum. 2010;62(10):3048–58.

    Article  PubMed  Google Scholar 

  30. • Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70(1):25–31. In this study, the ASAS members validated the new ASAS criteria for peripheral SpA in a cohort of 266 patients with a suspicion of SpA, and then in the entire ASAS study population of 975 patients. These new criteria performed well in patients presenting with peripheral arthritis, enthesitis, and/or dactylitis, but further studies are still needed to evaluate their performance in other settings.

    Article  PubMed  CAS  Google Scholar 

  31. Bakker C, Boers M, van der Linden S. Measures to assess ankylosing spondylitis: taxonomy, review and recommendations. J Rheumatol. 1993;20(10):1724–30.

    PubMed  CAS  Google Scholar 

  32. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol. 1994;21(12):2286–91.

    PubMed  CAS  Google Scholar 

  33. Lukas C, Landewe R, Sieper J, Dougados M, Davis J, Braun J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68(1):18–24.

    Article  PubMed  CAS  Google Scholar 

  34. • van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68(12):1811–8. This study reported the results of the validation process of the four ASDAS sets for AS in comparison with the BASDAI, its individual components, and physician and patient global assessment of disease activity, showing no major differences between the four ASDAS scores. Based on feasibility, the ASAS membership selected the ASDAS version that included back pain, duration of morning stiffness, patient global assessment, peripheral joint complaints, and CRP as the preferred version.

    Article  PubMed  Google Scholar 

  35. van der Heijde DM, van’t Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol. 1993;20(3):579–81.

    PubMed  Google Scholar 

  36. Machado P, Landewe R, Lie E, Kvien TK, Braun J, Baker D, et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis. 2011;70(1):47–53.

    Article  PubMed  Google Scholar 

  37. Pedersen SJ, Sorensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis. 2010;69(6):1065–71.

    Article  PubMed  Google Scholar 

  38. Aydin SZBA, Emery P, McGonagle D, Marzo-Ortega H. Disease activity assessment by ASDAS doesn’t predict sacroiliac inflammation with MRI in axial SpA [abstract]. Arthritis Rheum. 2010;62 Suppl 10:524.

    Google Scholar 

  39. Nas K, Yildirim K, Cevik R, Karatay S, Erdal A, Baysal O, et al. Discrimination ability of ASDAS estimating disease activity status in patients with ankylosing spondylitis. Int J Rheum Dis. 2010;13(3):240–5.

    Article  PubMed  Google Scholar 

  40. Aydin SZ, Can M, Atagunduz P, Direskeneli H. Active disease requiring TNF-alpha-antagonist therapy can be well discriminated with different ASDAS sets: a prospective, follow-up of disease activity assessment in ankylosing spondylitis. Clin Exp Rheumatol. 2010;28(5):752–5.

    PubMed  CAS  Google Scholar 

  41. Eder L, Chandran V, Shen H, Cook RJ, Gladman DD. Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis? Ann Rheum Dis 2010 Jul 13.

Download references

Acknowledgments

The work of Dr. Castillo-Gallego was funded by European League Against Rheumatism and Spanish Foundation of Rheumatology grants.

The work of Dr. Aydin was funded by an Articulum Fellowship, the Turkish Society for Research and Education in Rheumatology, and the Turkish Education Foundation.

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Hospital Universitario La Paz, Madrid, Spain

    Concepción Castillo-Gallego

  2. Leeds Institute of Molecular Medicine and Leeds NIHR Musculoskeletal Biomedical Research Unit, University of Leeds and Leeds Teaching Hospitals, NHS Trust, Leeds, UK

    Sibel Z. Aydin & Helena Marzo-Ortega

  3. Section of Musculoskeletal Disease, Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK

    Helena Marzo-Ortega

Authors
  1. Concepción Castillo-Gallego
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sibel Z. Aydin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helena Marzo-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Helena Marzo-Ortega.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castillo-Gallego, C., Aydin, S.Z. & Marzo-Ortega, H. Clinical Utility of the New ASAS Criteria for Spondyloarthritis and the Disease Activity Score. Curr Rheumatol Rep 13, 395–401 (2011). https://doi.org/10.1007/s11926-011-0194-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-011-0194-6

Keywords

Search

Navigation